SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as traders discuss Trump's potential executive action to reclassify marijuana, sparking hope for the cannabis sector. The community is debating the implications of rescheduling, potential short squeezes, and comparing TLRY to other cannabis stocks. Some are also expressing skepticism, citing past disappointments and the need for concrete action.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's stock is trending due to analyst target price updates and discussions around a recently revealed $10 billion custom AI chip order from Anthropic, now followed by an additional $11 billion order. While some see amazing earnings, others worry about gross margins and question a sky-high valuation; the community is closely watching for a potential dip-buying opportunity.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading session following a reverse stock split and recent ATM offering announcement, with community members debating whether the price action signals a pump and dump scheme or a genuine opportunity. Discussions revolve around the company's market cap requirements for Nasdaq compliance and speculation about potential news catalysts. The stock's low float and high short interest are also contributing to the intense speculation and trading activity.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is gaining traction, fueled by community enthusiasm and increasing buying pressure. Discussions highlight its potential within the Ethereum ecosystem, with some drawing comparisons to earlier memecoins and touting a possible 'prophecy' narrative. The community rallies around $YEE's momentum, anticipating further upward movement.

Knightscope, Inc. engages in the provision and development of security technology solutions. Its product portfolio includes the K1 stationary machine, the K3 indoor machine, the K5 outdoor machine, and the K7 multi-terrain four-wheel vehicle. Its machines patrol client sites without the need for remote control to provide a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area, and deter crime. The company was founded by William Santana Li and Stacy Dean Stephens on April 4, 2013 and is headquartered in Sunnyvale, CA.

Knightscope Inc - Ordinary Shares - Class A

Knightscope is trending due to a recently announced partnership with Palantir, generating excitement about potential expansion into the U.S. federal market. Community discussions revolve around the long-term potential of KSCP in the robotics and security sector, with some emphasizing its low market cap and others expressing skepticism based on past performance and dilution concerns. Some investors believe the partnership with Palantir could lead to significant growth and government contracts, while others are wary of pump-and-dump schemes.

Spirit Realty Capital is a Real Estate Investment Trust (REIT) company located in Scottsdale, Arizona.  Spirit Realty Capital was formed in 2003 to acquire single tenant, “operationally essential” real estate, which refers to generally free-standing, commercial real estate facilities where our tenants conduct retail, service or distribution activities that are essential to the generation of their sales and profits.

Realty Income Corp.

Realty Income ($O) is trending as investors weigh its potential amid fluctuating interest rate expectations and recent analyst rating adjustments. Community discussions revolve around its dividend reliability, global expansion, and comparison to peers like Digital Realty ($DLR) and Agree Realty ($ADC). Some are concerned about its growth prospects and exposure to retail tenants, while others see it as a stable income play for long-term investors, especially with potential rate cuts on the horizon.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH is trending as investors digest recent earnings and forward guidance, with community chatter focused on the CEO's commentary and the potential impact of tariffs. Some believe RH is undervalued and poised for a short squeeze, while others worry about the company's debt and exposure to the housing market.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

UNI is trending as the community discusses a potential proposal that could significantly reduce its circulating supply through token burns, potentially attracting institutional and retail interest. There is also discussion around how Keeta, a high-performance Layer 1 blockchain, complements Uniswap, offering settlement and interoperability solutions. The community sees potential for a supply shock and anticipates significant price movement if key governance unlocks occur.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending as investors discuss the company's deepening ties with major aerospace and defense players, including potential contracts with SpaceX. The community is highlighting the company's technology and its potential to revolutionize manufacturing for complex geometries. Many longs are expressing excitement, with some suggesting the stock could see significant upside.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM) is trending amid community excitement and speculation, with some users pointing to AI developments as a catalyst. Community members are actively discussing potential partnerships and bullish technical indicators, with some hoping for a significant price increase. However, there are also concerns about past performance and potential market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe and as a biosimilar to Xgeva 70 mg/mL single-use vial.</li><li>STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.&nbsp;</li><li>The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.</li></ul>Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and Xgeva, containing the active ingredient denosumab, and used widely to manage osteoporosis.According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193283/0/en/Alvotech-Announces-Approval-of-AVT03-a-Biosimilar-to-Prolia-and-Xgeva-denosumab-in-the-European-Economic-Area.html">to</a> Alvotech, the European denosumab market is currently valued at approximately $1.2 billion across all indications. While widely used to manage osteoporosis, it is also used to prevent skeletal-related events in patients with certain cancers. Osteoporosis is a disease in which your bones become weak and are more prone to fracture due to a decrease in bone mineral density and bone mass.<h2 class="st-heading-2">EC Approval</h2>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe for the treatment of osteoporosis and bone loss, and as a biosimilar to Xgeva 70 mg/mL single-use vial for the prevention of skeletal-related events in adults with advanced malignancies involving bone.AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. &nbsp;STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded flat in the pre-market session at the time of writing. On Stocktwits, retail sentiment around ALVO jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 61% this year and by 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT">Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Alvotech company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 

Equity

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 


<ul class="summary-bullets"><li>Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday.</li><li>The company said on Monday that data from across trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.</li><li>Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. &nbsp;</li></ul>Cantor Fitzgerald on Friday raised its price target on Cabaletta Bio (CABA) to $30 from $15 while keeping an ‘Overweight’ rating on the shares.The new price target represents over 1,000% potential upside to the stock’s closing price on Thursday.According to TheFly, the analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need.Scleroderma, also known as systemic sclerosis, is a group of autoimmune diseases that cause the hardening and tightening of the skin and connective tissues, and can also damage blood vessels and internal organs. It is characterized by the excessive buildup of collagen, which leads to fibrosis.<h2 class="st-heading-2">Cabaletta Presents Positive Data</h2>Cabaletta on Monday announced positive clinical data across trials evaluating Rese-cel. Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. It is administered as a single, weight-based infusion to reset the immune system and achieve durable clinical responses without the need for chronic therapy.The company said that the data from the trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.“We look forward to initiating the myositis registrational trial and anticipate alignment with FDA on the designs for lupus and systemic sclerosis this year,” said David J. Chang, Chief Medical Officer of Cabaletta, on Monday.While Myositis is a group of rare conditions characterized by muscle inflammation, Lupus is a chronic autoimmune disease where the body's immune system mistakenly attacks healthy tissues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CABA">CABA stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/60;" src="data:image/png;base64,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" width="621" height="60" alt="CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the company’s pipeline to generate substantial revenue in six years.<stembedurl>https://stocktwits.com/Bronco6970/message/634482351</stembedurl>CABA stock is up by 46% this year but has dropped 7% over the past 12 months. &nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pony-ai-stock-flips-between-gains-and-losses-after-key-shenzhen-permit/cLGqPQKR3U6">Pony AI Stock Flips Between Gains And Losses After Key Shenzhen Permit: Retail Expects Shares ‘Will Run Up In The Future’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cabaletta Bio logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock?

The analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need this represents. 

Is Invesco RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

Should Invesco RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

Tilray Brands, Inc. faces a regulatory reckoning: regain Nasdaq’s minimum bid price requirements soon or possibly get delisted from the exchange.&nbsp;The retail trading community on Stocktwits believes the cannabis and beer company will soon overcome this hurdle.Leamington, Canada-based Tilray received a non-compliance notice from Nasdaq on Tuesday after its stock failed to maintain the exchange’s $1 minimum closing bid price requirement for 30 consecutive business days.Shares of Tilray have lost more than half their value this year, as cannabis-linked stocks continue to struggle amid stalled federal legalization efforts.The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.If the company fails, it may transfer to the Nasdaq Capital Market for another 180-day extension — provided it meets other listing requirements and notifies Nasdaq of its plan to fix the issue, possibly through a reverse stock split.&nbsp;If Nasdaq still determines the company cannot regain compliance, its stock will face delisting.On Stocktwits, sentiment for Tilray ended on a slightly higher ‘bullish’ level on Wednesday amid a 45% jump in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/TLRY_sentiment_and_message_volume_as_of_Macrh_26_png_785b929906.webp" alt="TLRY sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>TLRY sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One user expressed hopes of Nasdaq being lenient with its process and said there were “zero” delisting fears because, with the extension, Tilray has until April 2026 to regain compliance.<stembedurl>https://stocktwits.com/Finance88/message/609341203</stembedurl>Another user said the company is “vertically scaled to be dominant from flower to drinks to pharma,” pointing to its products being available on the multinational supermarket chain Whole Foods, which is owned by Amazon.com.<stembedurl>https://stocktwits.com/Heb1972/message/609362664</stembedurl>Several retail investors on Stocktwits hope Tilray does not resort to a reverse stock split.<stembedurl>https://stocktwits.com/Rs1015/message/609258289</stembedurl>In January, Tilray’s stock was dealt a blow after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slides-after-q2-2025-results/chGWAd2RZD">reported</a> disappointing quarterly results and projected a $20 million revenue blow for 2025 from cutting back on certain alcohol beverage brands.Meanwhile, the company said Wednesday that the Massachusetts Superior Court dismissed a lawsuit filed by a shareholder against the company and its subsidiary Hexo.The plaintiff claimed Tilray failed to inform shareholders about Hexo’s corporate actions in late 2022 and its 2023 acquisition, allegedly causing financial losses. He sought nearly $8 million in damages.&nbsp;According to Koyfin data, short interest on Tilray has shot up from 12.7% at the start of the year to 17.3% as of the last week.The stock trades at a significant 180% discount to Wall Street’s average price target of $1.83. Out of 13 analysts covering it, nine rate it ‘hold’ and four ‘buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Retail Bulls See Nasdaq Compliance On The Horizon, Shareholder Lawsuit Victory Adds Cheer

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.

Shares of Tilray Brands tumbled over 12% on Thursday, hitting their lowest point since Dec. 20, as the cannabis and beer company reported disappointing fiscal second-quarter (Q2) results and projected a $20 million revenue blow for 2025.The company posted a Q2 net loss of $85.3 million, nearly doubling its year-ago loss of $46.2 million.&nbsp;Cannabis net revenue fell slightly to $66 million from $67 million in the prior year.&nbsp;While overall Q2 revenue rose 8.8% year-over-year to $211 million, it missed Wall Street’s estimate of $216.33 million.Tilray also launched “Project 420,” a $25 million initiative to streamline its beverage business.&nbsp;The plan involves cutting back on certain alcohol beverage brands,&nbsp;which will contribute to the $20 million anticipated revenue impact for fiscal 2025.&nbsp;The company cited prioritizing key products and discontinuing underperforming stock keeping units (SKUs) as reasons for the dip.&nbsp;For the six months ended Nov. 30, 2024, the company reported a $6.0 million reduction in net sales, driven by the prioritization of certain products in key markets.&nbsp;An additional $2.0 million decline resulted from the decision to discontinue specific SKUs due to market conditions, Tilray said.However,&nbsp;the firm expects the move to be offset by innovation in new beverage categories and brand extensions over the next 18 months.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TLRY_sentiment_and_message_volume_Jan_10_premarket_d6cc8d488d.png" alt="TLRY sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>TLRY sentiment and message volume Jan 10 as of 11 am ET | source: Stocktwits</figcaption></figure>Despite the underwhelming financial performance, retail investors on Stocktwits remained surprisingly bullish.&nbsp;Many speculated on the possibility of a reverse stock split and expressed optimism about management’s potential for a turnaround.&nbsp;<stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/Finer1m2/message/599547388</stembedurl><stembedurl>https://stocktwits.com/Big_Fish_76/message/599462909</stembedurl>There was also some solace in Tilray breaking even on an adjusted basis, outperforming analysts’ expectations of a $0.03 per share loss.<a href="https://stocktwits.com/symbol/TLRY">Tilray's stock</a> lost 34% in 2024.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tilray Stock Dips To 4-Week Low On $20M Revenue Blow Projection For 2025, But Retail’s Still Riding High

Tilray launched “Project 420,” a $25 million initiative to streamline its beverage business that involves cutting back on certain alcohol brands.

Shares of Sangamo Therapeutics ($SGMO) came under pressure in Monday’s after-hours trading session after the termination of the company’s collaboration agreement with Pfizer Inc. ($PFE) related to its hemophilia A gene therapy product, spiking retail chatter.Sangamo said it will gain development and commercialization rights to “giroctocogene fitelparvovec,” an investigational gene therapy product candidate for treating adults with ‘moderately severe’ to ‘severe hemophilia’ A that it co-developed with and licensed to Pfizer.Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner, the company said in a statement.Following the announcement, retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day ago. Message volumes climbed to ‘extremely high’ zone from ‘low’ in the same period.<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_31_at_3_06_34_PM_7cc280f2ef.png" alt="Screenshot 2024-12-31 at 3.06.34 PM.png" width="1256" height="302"><figcaption>SGMO sentiment meter and message volumes on Dec 31 as of 4:30 am ET</figcaption></figure><stembedurl>https://stocktwits.com/johnnydequino/message/598318745</stembedurl><stembedurl>https://stocktwits.com/stephanjk59/message/598298795</stembedurl>Meanwhile, Barclays kept an ‘Overweight’ rating with a $9 price target, saying that while Pfizer's (PFE) decision came as a big surprise given the prior comments of a Biologics License Application filing in early FY25, the stock move is "overdone," The Fly.com reported. A "limited valuation" was assigned to the HemoA program, said the report, citing the analyst.Sangamo is due to report quarterly earnings in March. Wall Street expects the company to post loss per share of around $0.09 in Q4 on estimated revenue of about $8.8 million, according to Stocktwits data.Sangamo stock is up 318% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious

Sangamo intends to explore all options to advance the program,

Shares of CommScope Holding Company Inc. ($COMM) rose 0.60% during Tuesday’s after-hours trading session following its announcement of a debt refinancing transaction to strengthen its capital structure, lifting retail sentiment.<a href="https://stocktwits.com/symbol/COMM">CommScope</a>, a provider of network connectivity solutions, entered the refinancing deal with its “first-lien” secured lenders, the company said. The debt refinancing will enable the company to address its upcoming 2025 and 2026 debt maturities and position the company for future success, it added.The first-lien lenders include funds managed by Apollo and Monarch Alternative Capital. The debt includes a new $3.15 billion first-lien term loan, maturing in 2029, and $1 billion in first-lien notes, maturing in 2031.Following the news, retail sentiment on Stocktwits was ‘extremely bullish’. Message volumes were &nbsp;at ‘extremely high’ levels.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_18_at_9_23_23_AM_ee9cb55050.png" alt="Screenshot 2024-12-18 at 9.23.23 AM.png"><stembedurl>https://stocktwits.com/varooommm/message/596894271</stembedurl><stembedurl>https://stocktwits.com/Curioustock/message/596886573</stembedurl><stembedurl>https://stocktwits.com/StockAutoPro/message/596471118</stembedurl>“This transaction is a pivotal step forward in our ongoing process to position CommScope for long-term growth,” Chuck Treadway, president and CEO of CommScope, said in a statement. &nbsp;“By successfully addressing our near-term maturities and greatly improving our pro forma leverage ratio, we move forward with the flexibility to focus on our core businesses and invest in the technology, products, and personnel to better deliver for our customers, and capitalize as the telecom industry recovers in the coming quarters."For its most recent quarter, the company’s non-GAAP adjusted net loss per diluted share narrowed to $0.05 from $0.12.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CommScope Holding Stock Rises On Strategic Refinancing: Retail’s Optimistic

The debt includes a new $3.15 billion first-lien term loan, maturing in 2029, and $1 billion in first-lien notes, maturing in 2031.

Shares of digital insurer Lemonade, Inc. (<a class="mention" data-mention="$LMND" data-symbol-id="LMND" href="https://stocktwits.com/symbol/LMND" target="_blank">$LMND</a>) surged over 6% in pre-market trading Wednesday, positioning the stock to hit near three-year highs if the momentum holds.&nbsp;The rally follows an upgrade from Morgan Stanley, which raised its rating on LMND to ‘Equal Weight’ from ‘Underweight’ and boosted the price target to $42 from $23, citing optimism about the company’s long-term growth potential after its recent investor day event.Morgan Stanley said Lemonade has "charted an ambitious goal" to grow its gross earned premiums (GEP) from $1 billion to $10 billion over the coming years.&nbsp;The brokerage praised the company’s “differentiated” AI-driven technology and its roadmap to achieve net profit positivity by the end of 2027 — well ahead of consensus estimates.An illustrative slide from Lemonade’s investor presentation reportedly suggested a potential valuation of $90 per share, assuming a 30% compound annual growth rate in GEP and a 12% adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio over seven years.&nbsp;That projection implies a 125% upside from the previous session’s close of just over $40.<figure class="image"><a href="https://stocktwits.com/symbol/LMND"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_20_at_6_15_37_PM_19d0e9dfa0.png" alt="Screenshot 2024-11-20 at 6.15.37 PM.png" width="1318" height="318"></a><figcaption>LMND sentiment and message volume on Nov 20 as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment mirrored the market’s enthusiasm, with the score flipping into the ‘extremely bullish’ zone pre-market.&nbsp;Discussions about Lemonade spiked significantly, reflecting renewed optimism around the stock’s future prospects.<stembedurl>https://stocktwits.com/OMillionaires/message/593297569</stembedurl>&nbsp;<stembedurl>https://stocktwits.com/KashChick/message/593297772</stembedurl>&nbsp;Last month, Lemonade reported third-quarter revenue of $136.6 million, up 19% year-over-year, driven by increases in premiums and investment income.&nbsp;While its adjusted EBITDA loss widened to $49 million from $40.2 million a year earlier due to growth-related spending, the company’s per-share loss of $0.95 came in better than the expected $1.00.LMND shares have gained over 135% year-to-date, outperforming broader market indices as investors increasingly bet on the company’s disruptive approach to the insurance industry.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/target-corporation-stock-plummets-premarket-after-q3-earnings-miss/cJ460tORXb">Target Stock Plummets Pre-Market After Q3 Earnings Miss, Lowered Guidance: Retail’s Worried About Tariff Impact</a>

Morgan Stanley said Lemonade has "charted an ambitious goal" to grow its gross earned premiums (GEP) from $1 billion to $10 billion over the coming years. 

Lemonade Stock Jumps Pre-Market As Morgan Stanley Upgrades On Growth Optimism: Retail Rides Along 

The brokerage praised the company’s “differentiated” AI-driven technology and its roadmap to achieve net profit positivity by the end of 2027.

Shares of Danimer Scientific ($DNMR) were down 12.76% as of 12:28 p.m. ET on Tuesday following the bioplastics maker’s third-quarter earnings, pushing down retail sentiment.Danimer is involved in the production of biodegradable plastic used by many consumer brands intent on replacing petroleum-based plastics. Among its PHA customers is Starbucks, which uses this material in its straws, and Mars Wrigley.Danimer’s revenues fell to $8.6 million in the third quarter from $10.9 million in the same period last year, roughly in line with Wall Street estimates of $8.58. While earnings per share (EPS) stood at -$7.20 compared to -$7.98 expected by Wall Street analysts.Its revenue specifically from PHA products fell to $6.6 million, reducing by $1.8 million from the year-ago period. It cited “reapportionment of Starbucks’ straw business” that led to significant disruptions in its order patterns. Richard N. Altice, Interim CEO of Danimer, said the company is focused on preserving liquidity and looking at a “variety of transactions” to strengthen its capital structure. Retail sentiment on the stock fell to ‘neutral’ (51/100) from ‘bullish’ (68/100) a day ago, while message volumes rose to ‘high’ (67/100) from ‘normal (48/100).<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_19_at_11_01_49_PM_a96736efff.png" alt="Screenshot 2024-11-19 at 11.01.49 PM.png" width="1304" height="290"><figcaption>DNMR sentiment meter and message volume on Nov 19 as of 12:31 pm| Source" Stocktwits</figcaption></figure>“We believe these headwinds are behind us, and it is important to reiterate that we have retained 100% of this business. We remain on track to continue to grow our PHA business into fiscal 2025,” Altice said in the statement.Altice noted the company is confident about the soft launch of 100% compostable Skittles packaging, which was featured at a Seattle Seahawks NFL game in October 2024. That packaging is made with its Nodax PHA resin.&nbsp; “While we remain focused on executing these commercial opportunities, we are mindful of managing our indebtedness levels and near-term constraints on liquidity as we enter our anticipated significant commercial ramp over the next twelve months,” Altice added. In May, Danimer received a non-compliance notice from the NYSE for maintaining an average closing price of not less than $1.00 per share over a period of thirty consecutive trading days. The notice did not result in the immediate delisting of the company's common stock from the NYSE.Danimer stock is down 83.17% year-to-date.&nbsp;For updates and corrections, email newsroom@stocktwits.com. &nbsp;

Danimer is involved in the production of biodegradable plastics| Image source: Pixabay

Danimer Scientific Stock Slips After Q3 Earnings; Retail Sentiment Wanes

Richard N. Altice, Interim CEO of Danimer, said the company is focused on preserving liquidity and looking at a “variety of transactions” to strengthen its capital structure. 

Invesco Capital Management LLC - Invesco RAFI US 1500 Small-Mid ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$47.79
Prev Close	$47.37
Open	$47.29
Dividend Yield	N/A
50-Day Moving Average	$45.44
Beta	N/A
Avg. Volume	94,792.84
PE Ratio	N/A

52-Week High	$47.87
52-Week Low	$32.53
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PRFZ
Invesco FTSE RAFI US 1500 Small-Mid ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PRFZ News

PRFZInvesco FTSE RAFI US 1500 Small-Mid ETF